Anavar 10mg/tab 105 Tabletten by Pharma Group

Usage

1. Obtain a pre-cycle bloodwork panel covering total testosterone, free testosterone, SHBG, LDL/HDL, haematocrit, ALT, and AST — this provides the baseline against which all mid-cycle and post-cycle values are compared.
2. Begin at 10 mg once daily in the morning, taken with or immediately after a small meal to support gastric tolerance and consistent absorption timing.
3. At the two-week mark, reassess subjective tolerance and, if bloodwork is available, check early ALT trends before deciding whether to advance to 20 mg daily.
4. If advancing to 20 mg, administer the second 10 mg tablet in the early afternoon — approximately 8–10 hours after the morning dose — to distribute androgenic exposure across the active portion of the day.
5. Complete a mid-cycle lipid and liver panel at weeks 4–6; use the HDL and ALT values to make a data-driven decision on whether to maintain, reduce, or end the Oxandrolone phase early.
6. Execute a step-down taper by returning to 10 mg once daily for the final 7–10 days before cessation, then schedule a post-cycle blood panel 3–4 weeks after the last tablet to confirm hepatic enzyme and lipid normalisation.

Warnings

Frequently asked questions

Can Oxandrolone be used alongside a standard testosterone TRT protocol for men over 40?

Yes — Oxandrolone is considered a TRT-adjunct by physicians managing age-related sarcopenia, not a replacement for testosterone. It occupies the androgen-receptor-dependent lean-mass slot without introducing aromatase substrate activity, so it does not add an estrogenic management burden to an already established TRT regimen. Most supervised adjunct protocols use 10–20 mg daily alongside a stable testosterone base.

What bloodwork markers should men over 40 track before and during an Oxandrolone anti-aging cycle?

Baseline panels should cover serum total testosterone, free testosterone, SHBG, LDL/HDL lipid fractions, haematocrit, and hepatic transaminases (ALT/AST). Oxandrolone suppresses HDL cholesterol — a confirmed finding from clinical lipid studies — and mildly elevates ALT in a dose- and duration-dependent manner, making mid-cycle and post-cycle lipid and liver panels operationally necessary for men in this demographic.

What role does Oxandrolone play in addressing age-related muscle loss and metabolic slowdown?

Oxandrolone counters two primary consequences of androgenic decline in older men: progressive lean-tissue catabolism and reduced androgen-receptor-mediated protein synthesis efficiency. Clinical data from burn-recovery and sarcopenia trials — including work cited in peer-reviewed endocrinology literature — demonstrate statistically significant lean-mass retention under Oxandrolone administration at doses below 20 mg/day, making it a pharmacologically grounded tool within physician-supervised anti-aging frameworks.

Why does the 10 mg tablet strength offer a practical advantage over higher-strength Oxandrolone formats in a TRT-adjunct context?

Men over 40 using Oxandrolone as a hormonal optimisation adjunct rarely require doses above 20 mg daily. The 10 mg unit maps precisely to that therapeutic window — one tablet for a conservative entry dose, two for a full adjunct dose — without requiring tablet splitting or dose estimation. Higher-strength tablets (25 mg or 50 mg) introduce per-dose inaccuracy at these conservative targets that the 10 mg format eliminates by design.

How does the 105-tablet pack align with typical anti-aging Oxandrolone cycle lengths?

At 10 mg once daily — a common starting point in physician-supervised anti-aging use — 105 tablets cover exactly 105 days, or approximately 15 weeks. At 20 mg daily (two tablets), the same pack provides a 7.5-week structured phase with zero waste. This non-standard count is a deliberate packaging decision that eliminates leftover tablets at the most commonly used low-to-moderate daily doses for this demographic. (2) angle_used

Manufacturer

Pharma Group's oral tablet product line — of which the Anavar 10 mg format is one of only a small number of SKUs — reflects the brand's deliberate policy of restricting tablet catalogue breadth in favour of applying injectable-grade analytical documentation to every oral compound it releases. The Oxandrolone tablet line specifically entered Pharma Group's portfolio with a product history tied to physician-adjacent demand: early adoption of this SKU was concentrated among users in TRT-monitoring communities seeking a documented-quality low-dose oral to accompany supervised testosterone protocols, a positioning that shaped the brand's decision to retain the 105-tablet count as the primary pack size rather than migrating to the 50- or 100-tablet formats common across competitor catalogues. The release file for each Anavar 10 mg batch is structured around two analytical checkpoints: API identity confirmation against a pharmacopoeial reference at raw-material intake, and per-tablet content-uniformity verification by reversed-phase HPLC at finished-product stage — the same dual-checkpoint architecture applied across the brand's ampoule lines. Tablet compression parameters, including hardness, disintegration time, and friability, are recorded within each batch record, providing a manufacturing audit trail that extends beyond API quantification into physical tablet performance.